Cargando…

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat

Epigenetic regulation of gene transcription by small molecule inhibitors of histone deacetylases (HDAC) is a novel cancer therapy. Vorinostat (Zolinza(™)) is the first FDA approved HDAC-inhibitor for treatment of patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duvic, Madeleine, Vu, Jenny
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721288/ https://www.ncbi.nlm.nih.gov/pubmed/19707308

Ejemplares similares

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma
por: Duvic, M, et al.
Publicado: (2006)

Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel
por: Denis, Daphné, et al.
Publicado: (2019)

Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL)
por: Kołkowski, Karol, et al.
Publicado: (2021)

The Skin Microbiome in Cutaneous T-Cell Lymphomas (CTCL)—A Narrative Review
por: Łyko, Magdalena, et al.
Publicado: (2022)

JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL)
por: Vadivel, Chella Krishna, et al.
Publicado: (2021)

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
por: Sato, Akinori
Publicado: (2012)

The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL)
por: Gantchev, Jennifer, et al.
Publicado: (2019)

28665 Cutaneous T-cell lymphoma (CTCL) outcomes during COVID-19
por: Garcia-Saleem, Tiffany J., et al.
Publicado: (2021)

Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations
por: Crimp, Caitlin, et al.
Publicado: (2022)

A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL)
por: Tsang, Matthew, et al.
Publicado: (2018)

Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL)
por: Ghazawi, Feras M., et al.
Publicado: (2019)

Cutaneous T-cell lymphoma (CTCL) exacerbation after viral vector COVID-19 vaccination
por: Panou, Evdoxia, et al.
Publicado: (2021)

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib
por: KieΔling, Michael K., et al.
Publicado: (2017)

Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries
por: Assaf, Chalid, et al.
Publicado: (2021)

International Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of CTCL outcomes during COVID-19
por: Geskin, Larisa J, et al.
Publicado: (2021)

Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description
por: D’Agostino, Paolo, et al.
Publicado: (2020)

Understanding itch in cutaneous T-cell lymphoma: Exploring the impact of comorbidities, treatment regimens, and racial differences on quality of life
por: Joshi, Tejas P., et al.
Publicado: (2022)

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
por: Petersen, D L, et al.
Publicado: (2014)

Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo
por: Mazuz, Moran, et al.
Publicado: (2020)

Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155
por: Litvinov, Ivan V, et al.
Publicado: (2013)

Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
por: Marzec, Michal, et al.
Publicado: (2011)

Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options
por: Joshi, Tejas P., et al.
Publicado: (2021)

Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients
por: Bagdonaite, Ieva, et al.
Publicado: (2015)

Retraction: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
Publicado: (2020)

Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox
por: Lewis, Daniel J., et al.
Publicado: (2017)

Targeting the non‐ATP‐binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T‐cell lymphoma (CTCL)
por: Zhang, Xu Hannah, et al.
Publicado: (2021)

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
por: Wang, Zhaohui, et al.
Publicado: (2023)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma
por: Gao, Minjie, et al.
Publicado: (2016)

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic
por: Zic, John A., et al.
Publicado: (2020)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
por: Khan, Shaheer, et al.
Publicado: (2019)

New JAK3-INSL3 Fusion Transcript—An Oncogenic Event in Cutaneous T-Cell Lymphoma
por: Velatooru, Loka Reddy, et al.
Publicado: (2023)

Teledermatology During COVID-19: An Updated Review
por: Farr, Morgan A., et al.
Publicado: (2021)

A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy
por: Washington, LaBaron T, et al.
Publicado: (2002)

Update on Biology of Cutaneous T-Cell Lymphoma
por: Phyo, Zaw H., et al.
Publicado: (2020)

New B-cell Lymphomas in the Setting of a Previous Rare Breast Implant–Associated B-cell Lymphoma
por: Messer, Alison, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_96dv83m6egfm4otrcmsiig25ln